Results 121 to 130 of about 10,024 (235)

Effectiveness of molnupiravir as early treatment for COVID-19 to prevent mortality and hospitalisation in high-risk adults: A systematic review and meta-analysis of randomised trials and real-world studies involving 1,612,082 patients.

Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi
BACKGROUND The efficacy of molnupiravir for COVID-19 treatment remains controversial due to substantial heterogeneity in dosage and study settings across randomised controlled trials (RCTs).
Shen-Hua Lin, Jen-Wei Liu, Yi-Ti Yen, Mong-Tan Chen, Jann-Tay Wang, Yu-Kang Tu, Chi-Tai Fang, Shan-Chwen Chang   +7 more
semanticscholar   +1 more source

Molnupiravir for the treatment of COVID-19 outpatients: An updated meta-analysis

Journal of Microbiology, Immunology and Infection
Background: The majority of available data on molnupiravir come from an unvaccinated COVID-19 population. Therefore, we conducted this meta-analysis to integrate evidence from recent randomized controlled trials (RCTs) as well as observational studies ...
Huzaifa Ahmad Cheema, Saleha Abdul Rab, Momina Butt, Uzair Jafar, Abia Shahid, Aqeeb Ur Rehman, Ka Yiu Lee, Syeda Sahra, Ranjit Sah   +8 more
doaj   +1 more source

Development and Validation of UV Method for Routine Analysis of Molnupiravir

Bangladesh Pharmaceutical Journal
A simple and cost-effective UV spectrophotometric method was developed and validated for the routine analysis of molnupiravir (MLP) using 10% (v/v) methanol as the solvent. The absorption maximum (λmax) of molnupiravir was determined to be 238 nm.
Shawkat Islam, Nusrath Jahan Fariha, Shakil Ahmed, Omar Faruk, Abu Shara Shamsur Rouf   +4 more
semanticscholar   +1 more source

Early administration of nirmatrelvir/ritonavir leads to faster negative SARS-CoV-2 nasal swabs than monoclonal antibodies in COVID 19 patients at high-risk for severe disease [PDF]

Purpose Besides the well-established efficacy in preventing severe COVID-19, the impact of early treatments, namely antivirals and monoclonal antibodies (mAbs), on the time length to negativization of SARS-CoV-2 nasal swabs is still unclear.
Antinori, Spinello, Bergna, Annalisa, Bernasconi, Davide, Borghetti, Silvia, Casalini, Giacomo, Colaneri, Marta, Colombo, Valeria, Corbellino, Mario, Cordier, Laura, Dedivitiis, Gianfranco, Fassio, Federico, Gabrieli, Arianna, Galli, Lucia, Gori, Andrea, Lai, Alessia, Riva, Agostino, Rizzardini, Giuliano, Scaglione, Giovanni, Schiavini, Monica, Sollima, Salvatore, Tarkowski, Maciej, Ventura, Carla Della, Visigalli, Debora   +22 more
core   +1 more source

Elucidation of the DNA repair mechanisms involved in the repair of DNA damage caused by the Arabinosides and Anti-COVID-19 drugs [PDF]

東京都立大学Tokyo Metropolitan University博士（理学）doctoral ...
RAHMAN, Md Ratul, ラーマン, モハッマド　ラートゥル   +1 more
core  

Molnupiravir’s authorisation was premature [PDF]

BMJ, 2022
openaire   +2 more sources

Molnupiravir increases SARS-CoV-2 genome diversity and complexity: A case-control cohort study [PDF]

Molnupiravir, an oral direct-acting antiviral effective in vitro against SARS-CoV-2, has been largely employed during the COVID-19 pandemic, since December 2021.
Antinori A., Berno G., Butera O., Carletti F., Fabeni L., Focosi D., Giombini E., Girardi E., Gruber C. E. M., Maggi F., Mastrorosa I., Mazzotta V., Nicastri E., Rosati S., Rueca M., Specchiarello E., Spezia P. G., Tucci F. G.   +17 more
core   +1 more source

Characteristics and outcomes of patients with COVID-19 at high risk of disease progression receiving sotrovimab, oral antivirals, or no treatment:a retrospective cohort study [PDF]

BACKGROUND: The clinical benefit of coronavirus disease 2019 (COVID-19) treatments against new circulating variants remains unclear. We sought to describe characteristics and clinical outcomes of highest risk patients with COVID-19 receiving early COVID ...
Birch, Helen J, Drysdale, Myriam, Gibbons, Daniel C, Kerr, William, Lloyd, Emily J, Macdonald, Calum, Patel, Vishal, Sheikh, Aziz, Tibble, Holly   +8 more
core   +3 more sources

Cost-effectiveness Analysis of Nirmatrelvir/Ritonavir Compared with Molnupiravir in Patients at High Risk for Progression to Severe COVID-19 in Japan

Journal of Health Economics and Outcomes Research
# Background Nirmatrelvir/ritonavir (NMV/r) and molnupiravir are oral antiviral drugs approved for the treatment of early symptomatic patients with mild to moderate COVID-19 at high risk of progression to severe disease in Japan.
Akira Yuasa, Hiroyuki Matsuda, Yosuke Fujii, Tendai Mugwagwa, Yuki Kado, Mizuki Yoshida, Koichi Murata, Yoshiaki Gu   +7 more
doaj   +1 more source

Effect of Nucleic Acid Analog Administration on Fluctuations in the Albumin-to-Globulin Ratio in Cats with Feline Infectious Peritonitis

Animals
Background: feline infectious peritonitis (FIP) is a fatal disease in cats classified as either effusive (‘wet’), non-effusive (‘dry’), or a mixture of both forms (‘mixed’).
Masato Katayama, Yukina Uemura, Daichi Katori   +2 more
doaj   +1 more source